Dr Harrington discusses PDS0101 plus pembrolizumab in HPV16+ HNSCC and how the VERSATILE-003 trial may change the HNSCC treatment paradigm.
Kevin Harrington, MD, PhD, FRCP, FRCR, FRSB
Advertisement
Articles by Kevin Harrington, MD, PhD, FRCP, FRCR, FRSB
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
Targeted Therapies, ADCs, and Oral SERD Combos Expand Treatment Possibilities Across Breast Cancer Settings
2
Head and Neck Oncologists Highlight Practice-Informing Research From ASCO 2026
3
Dr Galsky on the Current Roles of Biomarkers in Bladder Cancer
4
FDA Grants Priority Review to Adjuvant Atezolizumab Plus Chemotherapy for Stage III dMMR Colon Cancer
5